Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal CancerMichael J. Overman, Thierry André, Michael A. Morse et al.|Journal of Clinical Oncology|2018Cited by 2.1k
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142Thierry André, Michael J. Overman, Sara Lonardi et al.|Annals of Oncology|2022Cited by 253
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 StudyAkihito Kawazoe, Reinhard Depenbusch, Rui‐Hua Xu et al.|Journal of Clinical Oncology|2024Cited by 77